Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 5

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 5
---
 forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates, and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. These and other important factors, including those discussed in this prospectus under the headings “Prospectus Summary,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Business,” may cause our actual results, performance, or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements, or could affect our share price. Important factors that could cause actual results or events to differ materially from those expressed in forward-looking statements include, but are not limited to, the following: There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

| • |     | our ability to raise funds for general corporate purposes and operations, including our research activities and clinical studies; |

| • |     | our ability to realize the anticipated benefits of the merger (the “Kineta Merger”) with Kineta, Inc. (“Kineta”); |

| • |     | the effects of the Kineta Merger on our business relationships, operating results and business generally; |

| • |     | expectations regarding the strategies, prospects, plans, expectations and objectives of our management for future operations of our company following the closing of the Kineta Merger; |

| • |     | unexpected costs, charges or expenses resulting from the Kineta Merger; |

| • |     | our ability to recruit qualified management and technical personnel; |

| • |     | the cost, timing, scope and results of our clinical studies; |

| • |     | existing regulations and regulatory developments in the United States and other jurisdictions; |

| • |     | our ability to attract and retain key scientific, medical, commercial and management personnel; |

| • |     | our ability to obtain and maintain required regulatory approvals for our products; |

| • |     | our expectations regarding the use of our existing cash; |

| • |     | the therapeutic potential of IFx-Hu2.0, IFx-Hu3.0, TBS-2025 and future product candidates; |

| • |     | the regulatory approval processes of the U.S. Food and Drug Administration and other